tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
PremiumRatingsOptimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
29d ago
Immunovant Stockholders Approve Key Governance Decisions
Premium
Company Announcements
Immunovant Stockholders Approve Key Governance Decisions
30d ago
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
Premium
Ratings
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
1M ago
Immunovant Reports Progress and Financial Results
PremiumCompany AnnouncementsImmunovant Reports Progress and Financial Results
2M ago
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
Premium
Ratings
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
2M ago
Immunovant price target lowered to $57 from $58 at Citi
Premium
The Fly
Immunovant price target lowered to $57 from $58 at Citi
2M ago
Immunovant 3M share Block Trade priced at $17.85
PremiumThe FlyImmunovant 3M share Block Trade priced at $17.85
2M ago
Immunovant 3M share Block Trade; price range $17.85-$18.00
Premium
The Fly
Immunovant 3M share Block Trade; price range $17.85-$18.00
2M ago
Immunovant resumed with a Neutral at Goldman Sachs
Premium
The Fly
Immunovant resumed with a Neutral at Goldman Sachs
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100